HOSPIRA BORTEZOMIB 2.5 mg powder for injection vial

Šalis: Australija

kalba: anglų

Šaltinis: Department of Health (Therapeutic Goods Administration)

Veiklioji medžiaga:

bortezomib, Quantity: 2.5 mg

Prieinama:

Pfizer Australia Pty Ltd

Vaisto forma:

Injection, powder for

Sudėtis:

Excipient Ingredients: mannitol; nitrogen

Vartojimo būdas:

Intravenous, Subcutaneous

Vienetai pakuotėje:

1 vial/pack

Recepto tipas:

(S4) Prescription Only Medicine

Terapinės indikacijos:

Hospira Bortezomib Powder for Injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. Hospira Bortezomib Powder for Injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. Hospira Bortezomib Powder for Injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. Hospira Bortezomib Powder for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Produkto santrauka:

Visual Identification: White, to off white lyophilized powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorizacija statusas:

Licence status A

Leidimo data:

2017-11-03